Picard Medical

Q2 FY2026 EarningsQ2 FY26 results significantly exceeded top-line consensus with revenue of $2.95M vs. $1.55M expected, driven by a 38% YoY surge in U.S. product sales. Despite the revenue beat, operating losses widened to -$4.63M, significantly missing the consensus EBIT expectation of -$2.45M due to a 55% YoY spike in operating expenses. Diluted GAAP EPS of -$3.05 was technically 'better' than the -$1.50 mean consensus only due to a massive increase in the weighted average share count (1.86M vs 0.18M YoY) following aggressive debt-to-equity settlements and the May offering.